Nacuity Pharmaceuticals focuses on ocular diseases caused by oxidative stress in the retina, including age-related macular degeneration, glaucoma, and diabetic retinopathy. The $16.5M funding, led by the Foundation Fighting Blindness, will help advance two Nacuity clinical trials.
“This funding will help further our mission to develop a breakthrough treatment for retinitis pigmentosa and other serious blinding and chronic diseases," said Nacuity Chairman, CEO, and Co-founder Halden Conner.